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ABSTRACT
Background. Hypertension is extremely prevalent in patients with diabetes. Limited data exist on utili-
zation patterns of antihypertensive in this population are consistent with evidence-based practice guide-
lines.
Objective. To evaluate utilization patterns of antihypertensive agents among diabetic patients with hy-
pertension.
Design. Retrospective descriptive cross sectional.
Patients / Participants. 149 patients with diabetes and hypertension from outpatient department at Fam-
ily Medicine Hospital, Ahaderfieda. Khamis Mushait, K.S.A.
Results. Over 43% of patients were receiving calcium channel blockers (CCB), 36.2 % of received angio-
tensin converting enzyme inhibitors (ACEI), followed by angiotensin receptor blockers (ARBs) (34.9%), 
diuretics (34.2%) and β -blockers (16.2%). Patients on monotherapy were mostly receiving CCB (34.3%) 
and ACEI (29.9%). The majority (55.03%) of treated patients were on multidrug regimens. In patients 
with coronary artery disease (CAD), a diuretic with ACEI (25%) and calcium channel blocker with an-
giotensin receptor blocker (25%) was most commonly prescribed. 
Conclusions. Patterns of antihypertensive therapy were generally consistent with international guide-
lines. Areas of improvement include increasing ACEI/ARB and diuretic use, decreasing the number of 
untreated patients, and increasing the proportion of patients with controlled BP in this population.
Keywords: Hypertension, Diabetes, Antihypertensive agents.
RESUMEN
Antecedentes. La hipertensión es muy frecuente en los pacientes con diabetes. Existen datos limitados 
sobre los patrones de utilización de antihipertensivos en esta población consistentes con las guías de 
práctica basadas en la evidencia. 
Objetivo. Evaluar los patrones de utilización de antihipertensivos en los pacientes diabéticos con hi-
pertensión .
Diseño. Estudio retrospectivo descriptivo transversal.
Pacientes / Participantes. 149 pacientes con diabetes e hipertensión, del departamento de pacientes am-
bulatorios en el Hospital de Medicina Familiar, Ahaderfieda. Khamis Mushait, K.S.A.
Resultados. Más del 43% de los pacientes estaban recibiendo bloqueadores del canal de calcio (CCB), 
el 36,2% recibían inhibidores de la enzima convertidora de angiotensina (IECA), seguido de los bloque-
adores de los receptores de angiotensina (BRA) (34,9%), diuréticos (34,2%) y bloqueadores β (16,2 %). 
Los pacientes en monoterapia fueron la mayoría recibiendo CCB (34,3%) e IECA (29,9%). La mayoría 
(55,03%) de los pacientes tratados se encontraban en regímenes de múltiples fármacos. En los pacientes 
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con enfermedad de la arteria coronaria (CAD), se les prescribió con 
mayor frecuencia diurético con IECA (25%) y bloqueador de cana-
les de calcio con bloqueador del receptor de angiotensina (25%). 
Conclusiones. Los patrones de utilización de antihipertensivos 
fueron generalmente consistentes con las directrices internacion-
ales. Las áreas de mejora incluyen el aumento de IECA / ARB y el 
uso de diuréticos, disminuyendo el número de pacientes no trata-
dos, y el aumento de la proporción de pacientes con PA controlada 
en esta población. 
Palabras clave: hipertensión, diabetes, agentes antihipertensivos.
INTRODUCTION
Diabetes mellitus and hypertension are interrelated diseas-
es that strongly predispose an individual to atherosclerotic 
cardiovascular disease 1. The prevalence of coexisting hy-
pertension and diabetes appears to be increasing in Saudi 
Arabia. The World Health Organization estimates that the 
number of people with diabetes mellitus is projected to in-
crease almost threefold in Saudi Arabia, from 890,000 in 2000 
to a staggering 2,523,000 in 2030 2. Hypertension (HTN), 
affects about 21% of all Saudi adults between the ages of 
18 and 64 years, is an important modifiable risk factor for 
cerebrovascular disease (CVD) 3. Studies such as Framing-
ham heart study, United Kingdom Prospective Study-39 
(UKPDS), Hypertension Optimal Treatment (HOT), Sys-
tolic Hypertension in the Elderly Programme (SHEP), Sys-
tolic hypertension in Europe (SYST-Eur), Hypertension in 
the Very Elderly Trial (HYVET-Pilot) indicated that reduc-
tion in either isolated systolic or systolic-diastolic hyper-
tension significantly reduces the risk of micro and macro 
vascular complications and cardiovascular (CV) death or 
diabetes-related death 4. The Seventh Joint National Com-
mittee (JNC 7) and American Diabetes Association (ADA) 
recommends that blood pressure (BP) in diabetics be con-
trolled to levels of 130/80 mmHg or lower 5. Whatever the 
goal level, rigorous control of BP is paramount for reducing 
the progression of diabetic nephropathy to end stage renal 
disease 6. However, studies consistently demonstrate that 
most diabetic patients do not achieve recommended levels 
of BP control, and the majority have a BP of >140/90mmHg 
7. Saudi Hypertension Management Guidelines recom-
mend either an ACE-I or an ARB, if ACE-I is not tolerated. 
If BP targets are not achieved, a thiazide diuretic should 
be added to those with an e Glomerular Filtration Rate ≥ 
30 or a loop diuretic for those with an estimated Glomeru-
lar Filtration Rate < 30 8. Some studies have demonstrated 
the beneficial effects of beta blockers and calcium channel 
blockers in diabetic hypertensive patients 9. On contrary to 
above studies, some studies indicate that majority of dia-
betic patients will require two or more drugs to achieve BP 
control 8, 10, 11. The resulting changes in drug use in time and 
place may have medical, social and economic implications 
both for the individual patient for populations. These dif-
ferences need to be identified, explained and corrected if 
needed. Drug utilization studies are necessary to this effect 
with a particular focus on socio- demographic character-
istics, co-morbid conditions and pattern of anti- hyperten-
sive drugs usage 12. Thus in this context, the present study 
was conducted to examine the utilization pattern of anti-
hypertensive in hypertensive diabetic patients and also to 
explore the adherence of prescribing pattern with existing 
guidelines. 
MATERIALS AND METHODS
This study is a retrospective descriptive cross sectional drug 
utilization study conducted in the outpatient department at 
Family Medicine Hospital, Ahaderfieda. Khamis Mushait, 
K.S.A. A total of 149 prescriptions of hypertensive outpa-
tients with diabetes above 18 yrs of age were randomly se-
lected employing systematic sampling. The demographic 
and medication history of the diabetic hypertensive pa-
tients were collected to address the following questions: 
1. Which antihypertensive drug classes and combinations, 
respectively, are applied by general physicians in hyper-
tensive diabetic patients? 
2. Did drug treatments differ with respect to certain patient 
characteristics such as age, gender? 
Data analysis
Data analysis was carried out using Microsoft excel. Data 
were expressed as mean (standard deviation) for continu-
ous variables and as frequency for categorical variables.
RESULTS
One hundred forty nine prescriptions belonging to 81 (54.4 
%) females and 68 (45.6%) males were studied. The mean 
age of the male patients included in the study was found to 
be 55.2±8.5 years and the mean age of the female students 
included in this study was found to be 58.1 ± 12.9.
The overall use of antihypertensive in diabetes is shown 
in Table 1. The utilization of the calcium channel blockers 
supersedes all other groups of antihypertensive in diabetes 
with hypertension. Use of the calcium channel blockers is 
around 43% in hypertensive diabetic patients. Amlodipine 
is the predominantly used CCB. The ACE inhibitors are the 
antihypertensive class used the most following the CCB’s 
(36.2%). The use of angiotensin II receptor blockers were 
also nearly the same as ACE inhibitors among the diabetes 
patients with diabetes (34.9%). Next to the ARBs, diuret-
ics were used widely among these patients (34.2%) and 
the loop diuretic furosemide is the least prescribed diu-
retic in diabetes with hypertension. β-Blockers are the least 
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prescribed antihypertensive in diabetes with hyperten-
sion. Table 2 shows the relative use of antihypertensive in 
both genders. Marked gender based differences have been 
found to be there between the two groups of diabetes. The 
utilization of ARBs, β-Blockers and CCBs are more among 
the female patients whereas the utilization of ACE inhibi-
tors and diuretics are high among the male patients. 
In Table 3 the various antihypertensive drugs and the num-
ber of patients in whom they were used under the class 
of monotherapy revealed that, out of 67 patients who un-
derwent monotherapy for the treatment of hypertension, 
23 (34.3%) of the patients were prescribed with CCBs, fol-
lowed by 20 (29.9 %) with ACE inhibitors, 14 (20.8%) of the 
patients with ARBs, 6 (9%) of the patients with diuretics 
and 4 (6%) of the patients with β-blockers.
Table 4 reveals that, out of 68 patients in whom two anti-
hypertensive were prescribed, 17(25%) patients were pre-
scribed with a combination of Diuretics & ACE inhibitors 
and another 17(25%) patients were prescribed with a com-
bination of CCB & ARBs followed by 13 (19.1%) of patients 
with Diuretics and ARBs, 7(10.3% ) patients with ACE inhib-
itors, 3 (4.4%)patients with ACE inhibitors and β-Blockers, 
2 (2.9%) patients were prescribed with β-Blockers+ARB, an-
other 2 (2.9 %) patients were prescribed with CCB+Diuretcs 
and 1 (1.5%) was prescribed with β-Blockers+diuretics.
Table 1: Antihypertensive Drug Use in Diabetics
S.No Antihypertensive Class Drug Nº of Prescriptions Percentage
1 CCB
Amlodipine 59 39.6
Nifedipine 5 3.4
Total 64 43
2 ACEI
Captopril 3 2
Perindopril 51 34.2
Total 54 36.2
3 β-Blockers
Atenolol 8 5.4
Bisoprolol 11 7.4
Carvedilol 5 3.4
Total 24 16.2
4 ARBs
Valsartan 27 18.1
Candesartan 22 14.8
Losartan 2 1.3
Telmisartan 1 0.7
Total 52 34.9
5 Diuretics
Furosemide 9 6
Hydrochlorthiazide 22 14.8
Indapamide 20 13.4
Total 51 34.2
[Calcium channel blockers (CCB), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs)] 
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Table 2: Relative use of antihypertensive in males and females
S.No Antihypertensive class
Males
N (%)
Females
N (%)
1 CCB 25 (36.8) 39 (48.1)
2 ACEI 37 (54.4) 17 (21)
3 β-Blockers 8 (11.8) 16 (19.8)
4 ARBs 22 (32.4) 30 (37)
5 Diuretics 26 (38.2) 25 (31)
[Calcium channel blockers (CCB), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs)] 
Table 3: Pattern of prescribed single antihypertensive agent (n=67)
S.No Antihypertensive Class Number of prescriptions Percentage
1 Diuretics 6 9
2 β-Blockers 4 6
3 Calcium Channel Blockers 23 34.3
4 ACE Inhibitors 20 29.9
5 ARBs 14 20.8
[Calcium channel blockers (CCB), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs)] 
Table 4: Pattern of use of antihypertensive drug combinations
Drug combination No of prescriptions % of total prescriptions
2 Drug combination n=68 45.63%
ARB+Diuretics 13 19.1
CCB+ARB 17 25
β-Blockers+ARB 2 2.9
CCB+Diuretcs 2 2.9
β-Blockers+diuretics 1 1.5
CCBs + β-Blockers 6 8.8
ACEI+ Diuretics 17 25
ACEI + CCBs 7 10.3
ACEI + CCBs 3 4.4
3 Drug combination n=13 8.72%
ACEI + β-Blockers + CCBs 2 14.3
ACEI + β-Blockers + Diuretics 1 7.1
ACEI + CCBs+ Diuretics 3 21.4
β-Blockers+ARB+diuretics 3 21.4
CCB+ARB+Diuretics 3 21.4
CCB+ β-Blockers +Diuretics 1 7.1
4 Drug combination n=1 0.67%
β-Blockers +ACEI + CCBs+ Diuretics 1 7.1
[Calcium channel blockers (CCB), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs)] 
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DISCUSSION
We studied patterns of antihypertensive use in patients 
with diabetes and hypertension, to evaluate whether they 
were consistent with evidence-based practice guidelines. 
In present study, ACEI, ARBs and calcium channel blocker 
were more commonly prescribed drugs, followed by, diu-
retics and beta-blockers irrespective of mono or poly thera-
py. Majority of patients were on polytherapy in the present 
study. As the hypertensive patients were diabetic increased 
utilization of ACE inhibitors was observed which was in 
accordance with JNC-7 guidelines which recommend its 
use for renoprotection in the hypertensive diabetic patients 
13. Among all the ACEI, perindropirl (34.2%) was widely 
prescribed than any other ACEI. This finding is supported 
by the EUROPA study which indicated that among patients 
with stable coronary heart disease without apparent heart 
failure, perindopril can significantly improve outcome14. 
We found that men were significantly more likely to be pre-
scribed an ACE inhibitor as initial antihypertensive thera-
py than women (54.4 vs. 21%) this may be due to the fact 
that men are at high risk of developing atherosclerosis com-
pared to women and also because of the teratogenic risk of 
ACEI and also reports from clinical trials have consistently 
documented that women are at higher risk of ACE inhibi-
tor-induced cough than men 15. Though 34.3% of patients 
received calcium channel blockers as monotherapy, some 
studies have shown an excess of selected cardiac events 
in patients treated with dihydropyridine calcium channel 
blockers (DCCBs) compared with ACEI 16. 
In a meta-analysis of 42 trials published by Wald et al., it 
was found that combining antihypertensive drugs from 
two different classes lowered blood pressure five times 
more than doubling the dose of a single agent 17. In addi-
tion to synergistic blood pressure lowering, combination 
therapy allows for lower dosage requirements of each in-
dividual agent. This, in turn leads to decreased side effects, 
thereby improving compliance 18. In our present study use 
of multiple drug combinations for controlling blood pres-
sure was also high at 55% compared to those using single 
drug 44.9% in these patients. Our finding is similar to those 
observed by Anand et al. 19 and Gu et al. 20 who indicated 
that the increased use of multiple antihypertensive drugs 
apparently has contributed to substantial improvement in 
BP control in the treated hypertensive population. A combi-
nation of diuretics and ACE inhibitor (ACEI) were the im-
portant drug combination to be most commonly prescribed 
in our study and also diuretics were used more often as 
component of multidrug therapy. This is supported by a 
previous report which indicated that ACEI–diuretic combi-
nations achieve blood pressure control in approximately 80 
percent of patients 21. 
In the present investigation, two-drug combinations were 
mostly prescribed (45.63%), followed by three-drug com-
binations (8.27%) and four drug combinations (0.67%) 
(Table 4). In two-drug combinations, a diuretic with ACEI 
(25%) and calcium channel blocker with angiotensin recep-
tor blocker (25%) was most commonly prescribed as it is 
a choice for the treatment of the majority of patients with 
hypertension, particularly those at high risk of a second-
ary event 22, the combined therapy with an ARB and a CCB 
has a potentially useful antiproteinuric effect in patients 
with type 2 diabetic nephropathy, even when their renal 
function is reduced 23 followed by an ARB with a diuretic 
(19.1 %). ONEAST study results confirm that ARB / diu-
retic combinations reduce BP further than monotherapies 
in hypertensive diabetic subjects with an acceptable safety 
profile 23.
CONCLUSIONS
Although this study lacks both breadth and depth, how-
ever it provides a reasonable indication of the prescrip-
tion patterns of antihypertensive agents in diabetic hyper-
tensive population. Our findings suggest that CCBs and 
ACE inhibitors were used in large proportion of diabetic 
hypertensive patients and the pattern of antihypertensive 
therapy was generally consistent with JNC 7 guidelines, 
those being the current guidelines at the time of our study. 
However, there remains potential room for improvement 
in drug utilization and a critical need for better blood pres-
sure control. Further research is needed to qualify rationale 
for choice of drug based on demographic data, economic 
status, concomitant conditions and complications to give 
additional insight into prescribing patterns of antihyper-
tensive in diabetic patients of Aseer region of Saudi Arabia.
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